Clinical trial
A Phase II Trial Of Lovastatin And Pembrolizumab In Patients With RM HNSCC (LAPP)
NCT06636734 is registered in ClinicalTrials.gov with Emory University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial Of Lovastatin And Pembrolizumab In Patients With RM HNSCC (LAPP)
- Lead sponsor
- Emory University
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- December 9, 2024
- Completion date
- December 31, 2028
- Enrollment
- 28 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
clinical stage iv hpv-mediated (p16-positive) oropharyngeal carcinoma ajcc v8, human papillomavirus-related neck squamous cell carcinoma of unknown primary, metastatic head and neck squamous cell carcinoma, metastatic hypopharyngeal squamous cell carcinoma, metastatic laryngeal squamous cell carcinoma, metastatic nasopharyngeal squamous cell carcinoma, metastatic oral cavity squamous cell carcinoma, metastatic oropharyngeal squamous cell carcinoma, metastatic paranasal sinus squamous cell carcinoma, recurrent head and neck squamous cell carcinoma, recurrent hypopharyngeal squamous cell carcinoma, recurrent laryngeal squamous cell carcinoma, recurrent nasopharyngeal squamous cell carcinoma, recurrent oral cavity squamous cell carcinoma, recurrent oropharyngeal squamous cell carcinoma, recurrent paranasal sinus squamous cell carcinoma, stage iv hypopharyngeal carcinoma ajcc v8, stage iv laryngeal cancer ajcc v8, stage iv lip and oral cavity cancer ajcc v8, stage iv nasopharyngeal carcinoma ajcc v8, stage iv oropharyngeal (p16-negative) carcinoma ajcc v8, stage iv sinonasal cancer ajcc v8